Flash Finance

Infinium Pharmachem LimitedINFINIUMCorporate

Pharmaceuticals - Indian - Bulk Drugs Latest results: Mar 2026 7 quarters of data
Consolidated Standalone
₹313.60
MCap ₹489 Cr · P/E 35.9
Infinium Pharmachem Limited — Stock analysis & AI research Infinium Pharmachem Limited — Seasonality — best & worst months Infinium Pharmachem Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹106 Cr
Sales · Mar 2026
+45.2% YoY
₹11 Cr
Operating Profit · Mar 2026
+37.5% YoY
10.4%
OPM % · Mar 2026
-5.5% YoY
₹8 Cr
Net Profit · Mar 2026
+166.7% YoY
₹4.20
EPS · Mar 2026
+75.0% YoY

📝 Infinium Pharmachem Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Infinium Pharmachem Limited reported revenue of ₹106 crore for the quarter ended March 2026 (Q4 FY26), up 45.2% from ₹73 crore in the same quarter last year.

Net profit rose 166.7% year-on-year to ₹8 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹4.20.

Operating profit stood at ₹11 crore — an operating margin (OPM) of 10.4%, compared with 11.0% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹190 crore with a net profit of ₹14 crore.

Valuation snapshot

At the current price of ₹313.60, INFINIUM has a market capitalisation of ₹489 crore and a trailing P/E of about 35.9.

Within the Pharmaceuticals - Indian - Bulk Drugs industry, it is the 7th-largest of the 11 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 64.91%, domestic institutional investors (DIIs) 0.21%, public shareholders 34.87% of Infinium Pharmachem Limited.

Promoter holding rose from 59.91% to 64.91% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹489 Cr
Current Price ?
₹313.6
P/E ?
35.93above ind
Industry P/E ?
32.10
P/B ?
4.04
P/S ?
2.57
P/FCF ?
20.36
Enterprise Value ?
₹489 Cr
EV/EBITDA ?
22.79
PEG ?
3.99
Earnings Yield ?
3.7%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹190 Cr
OPM ?
11.3%
Profit after tax (TTM) ?
₹14 Cr
EPS (TTM) ?
₹8.73
ROCE ?
13.0%
ROE ?
11.2%
ROA ?
7.8%
Growth
Sales — latest qtr ?
₹106 Cr
PAT — latest qtr ?
₹8 Cr
YoY qtr sales growth ?
45.2%
YoY qtr profit growth ?
166.7%
Sales growth (3y) ?
18%
Sales growth (5y) ?
22%
Profit growth (3y) ?
9%
Profit growth (5y) ?
35%
Financial Health
Debt ?
₹0 Cr
Debt to Equity ?
0.00
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
64.91%
Change in promoter holding ?
-0.33%
Pledged percentage ?
N/A
Market
Return 3 months ?
49.7%
Return 6 months ?
52.9%

🗓️ Quarterly results (7 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Sep 2022Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026 YoY % QoQ %
Sales 796174837384106 +45.2% —
Operating Profit 9108881011 +37.5% —
Other Income 1011111 +0.0% —
Interest 1112221 -50.0% —
Depreciation 0112222 +0.0% —
Profit Before Tax 88765810 +100.0% —
Net Profit 6654368 +166.7% —
EPS 5.404.463.663.172.403.594.20 +75.0% —
OPM % 11.4% 16.4% 10.8% 10.2% 11.0% 12.4% 10.4% -5.5% —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 5141616 +0.0%
Reserves 174594105 +11.7%
Borrowings 2911520 -100.0%
Other Liabilities 19153754 +45.9%
Total Liabilities 7185198175 -11.6%
Fixed Assets 19202423 -4.2%
CWIP 0018 +700.0%
Investments 002929 +0.0%
Other Assets 5266144114 -20.8%
Total Assets 7185198175 -11.6%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
CFO/OP 73%-51%-131%174% +232.8%
Cash from Operating Activity 9-13-2934 +217.2%
Cash from Investing Activity -5-4-27-7 +74.1%
Cash from Financing Activity -32379-32 -140.5%
Net Cash Flow 1623-5 -121.7%
Free Cash Flow 1-17-3824 +163.2%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 49557961 -22.8%
Inventory Days 898713796 -29.9%
Days Payable 31163810 -73.7%
Cash Conversion Cycle 108126178146 -18.0%
Working Capital Days 27969799 +2.1%
ROCE % 36%28%15%13% -13.3%

👥 Shareholding (latest 4 periods)

Metric Nov 2024Mar 2025Sep 2025Mar 2026 % Chg
Promoters 65.24%65.24%59.91%64.91% +8.3%
DIIs 0.00%0.00%0.02%0.21% +950.0%
Public 34.76%34.76%40.07%34.87% -13.0%
No. of Shareholders 9989581,0521,061 +0.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs · 11 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SMSPHARMA SMS Pharmaceuticals ₹442.45 4,144 39.7 898 102 19.3% 11.4% 13.3% 48.6% 5.6% -1.4%
2 AARTIDRUGS Aarti Drugs ₹428.30 3,909 20.5 2,678 191 12.4% 7.1% 7.5% 16.3% 18.9% -7.2%
3 HIKAL Hikal ₹229.83 2,834 — 1,734 -34 13.4% -2.0% -8.0% -154.4% 6.0% 67.0%
4 BETA Beta Drugs ₹2,064.90 2,084 37.5 513 57 20.5% 11.2% — — 25.5% 31.7%
5 NGLFINE NGL Fine-Chem ₹2,786.60 1,722 30.1 536 57 15.6% 10.6% 36.0% 123.2% 33.6% 99.1%
6 ANUHPHR Anuh Pharma ₹92.99 932 21.1 779 44 8.6% 5.7% 16.5% -12.8% 4.2% 42.8%
7 INFINIUM Infinium Pharma ₹222.95 347 31.2 190 14 11.3% 7.2% — — 45.2% 166.7%
8 AAREYDRUGS Aarey Drugs ₹98.71 329 67.1 415 4 1.6% 1.0% -0.4% 12.3% -56.3% -25.3%
9 PAR Par Drugs ₹128.90 159 10.9 109 14 18.3% 13.3% 2.7% -1.9% 20.1% 41.6%
10 KREBSBIO Krebs Biochemicals ₹57.94 125 — 25 -14 -10.0% -55.9% -45.2% 37.1% 27.4% 53.3%
11 VILINBIO Vilin Bio ₹18.00 27 14.2 42 2 7.6% 4.6% — — 215.9% 1680.0%
❓ Frequently asked questions
What was Infinium Pharmachem Limited's revenue in Q4 FY26?
Infinium Pharmachem Limited reported revenue of ₹106 crore for the quarter ended March 2026 (Q4 FY26), up 45.2% from ₹73 crore in the same quarter last year.
What was Infinium Pharmachem Limited's net profit in Q4 FY26?
Net profit rose 166.7% year-on-year to ₹8 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹4.20.
What is INFINIUM's market capitalisation and P/E ratio?
At the current price of ₹313.60, INFINIUM has a market capitalisation of ₹489 crore and a trailing P/E of about 35.9.
Who owns Infinium Pharmachem Limited? (shareholding pattern)
As of Mar 2026, promoters held 64.91%, domestic institutional investors (DIIs) 0.21%, public shareholders 34.87% of Infinium Pharmachem Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI